Skip to main content
SpringerLink
Log in
Book cover

Neuro-Psychopharmaka Ein Therapie-Handbuch pp 597–604Cite as

Pentoxifyllin

  • Chapter

  • 87 Accesses

Zusammenfassung

Pentoxifyllin (1-(5-oxyohexyl)-3,7dimethylxanthine, 1-(5-oxyohexyl)theobromine), ein Methylxanthin-Derivat, ist ein in der Mikrozirkulation wirksames Hämorheologicum, das zu einer Senkung der Blutviskosität, Normalisierung der verminderten Erythrozytenverformbarkeit sowie Hemmung der Erythrozytenund Thrombozytenaggregation führt. Zu den Wirkungen gehören ferner die Stimulierung der Freisetzung von Prostazyklin in vitro, die Hemmung der Freisetzung plättcheneigener Mediatoren, die Senkung erhöhter Fibrinogenspiegel, die Verminderung der Adhäsivität der Leukozyten am Endothel sowie die Verminderung der Leukozytenaktivierung und dadurch bedingte Endothelschäden. In der derzeitigen Therapieforschung steht die Untersuchung des therapeutischen Potentials von der durch Pentoxifyllin bedingten Hemmung des Tumor-Nekrosefaktors (TNF)-α und Effekte auf Immunmodulatoren im Vordergrund.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aviado DM, Porter JM (1984) Pentoxifylline: a new drug for the treatment of intermittent claudication — mechanisms of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 4: 297–307

    PubMed  CAS  Google Scholar 

  • Andreeva NJ, Gegutschadze MD, Gelashwili AP, Yipiani VA, Natadze TG et al. (1979) The effect of pentoxifylline on regional vascular systems. Curr Med Res Opin 6 [Suppl 4]: 57–59

    Article  CAS  Google Scholar 

  • Angelides NS (1986) Continuous infusion treatment with pentoxifylline in patients with severe peripheral vascular occlusive disease. Angiology 37: 555–564

    Article  PubMed  CAS  Google Scholar 

  • Angelkort B (1977) Influence of pentoxifylline (Trental 400) on microcirculation, post-stenotic blood pressure and walking capacity in patients with chronic occlusive arterial disease. IRCS Med Sci 5: 370

    Google Scholar 

  • Angelkort B (1979) Thrombozytenfunktion, plasmatische Blutgerinnung und Fibrinolyse bei chronisch arterieller Verschlußkrankheit. Med Welt 30: 1239–1248

    PubMed  CAS  Google Scholar 

  • Angelkort B (1981) Coagulation phenomena and blood fluidity in peripheral occlusive arterial disease. Study with pentoxifylline. In: Manrique U, Müller WE (eds) Disorders of blood flow; new therapeutic aspects. Excerpta Medica, Amsterdam, pp 68–79

    Google Scholar 

  • Angelkort B, Doppelfeld E (1983) The treatment of chronic arterial occlusion: a clinical study with a new formulation of pentoxifylline (Trental 400). Pharmatherapeutica 3 [Suppl I]: 18–29

    Google Scholar 

  • Arzneimittelkompendium der Schweiz (1996) Black RS, Barclay LL, Nolan KA, Thaler HW, Hardiman ST, Blass JP (1992) Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc 40:237–244

    Google Scholar 

  • Bluhm RE, Molnar J, Cohen MM (1985) The effect of pentoxifylline on the energy metabolism of ischemic gerbil brain. Clin Neuropharmacol 8: 280–285

    Article  PubMed  CAS  Google Scholar 

  • Bluhm RE, Cohen MM (1978) Protection by pentoxifylline against ischemic deterioration of cerebral metabolism. Neurology 28: 378

    Google Scholar 

  • Flamm P, Lehrach F, Weiser HG (1978) Durchblutungsstörungen des Netzhaut-Aderhaut-Bereichs und ihre Behandlungsmöglichkeiten mit Pentoxifylline. Therapiewoche 28: 9911–9918

    Google Scholar 

  • Gabaschwili VM, Kobaladze SG, Schakaraschwili RR, Virsaladze MD, Petriaschwili SP et al. (1979) The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. Curr Med Res Opin 6 [Suppl 4]: 25–29

    Article  Google Scholar 

  • Hartmann A (1985) Comparative randomized study of cerebral blood flow after long-term administration of pentoxifylline and codergocrine mesylate in patients with chronic cerebrovascular disease. Curr Med Res Opin 9: 475–479

    Article  PubMed  CAS  Google Scholar 

  • Hartmann A (1986) Haemorheoiogical treatment of acute cerebral ischaemia. In: Gotoh Y, Lechner H (eds) Clinical haemorheology — a new approach to cerebrovascular disease. Royal Society of Medicine Services, London, pp 65–73

    Google Scholar 

  • Hartmann A, Alberti E, Lange D (1979) Effect of pentoxifylline on regional CBF and CBV in dementia. Acta Neurol Scand 60 [Suppl 72]: 624–625

    Google Scholar 

  • Herskovits E, Vazquez A, Famulari A, Tamaroff L, Fraiman H, Gonzales AM et al. (1980) A randomised clinical trial of pentoxifylline and antiaggregants in recent transient ischemic attacks. A one-year follow-up. Proceedings of Conference on Blood Rheology and Microcirculation, Capri, Italy

    Google Scholar 

  • Hinze HJ (1971a) Analysis of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine, part 1. The spectroscopy of 3,7-dimethyl-1-(oxo-hexyl)-xanthine. Arzneimittelforschung/Drug Res 21: 1456–1459

    CAS  Google Scholar 

  • Hinze HJ (1971b) Analysis of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine, part 2. Chromatography and quantitative estimation of BL 191. Arzneimittelforschung/Drug Res 21: 2045

    CAS  Google Scholar 

  • Hinze HJ (1972) The pharmacokinetics of 3,7-dimethyl-1-(5-oxo-hexyl)xanthine (BL 191) in man. Arzneimittelforschung/Drug Res 22: 1492–1495

    CAS  Google Scholar 

  • Hinze HJ, Bedessem G, Sdder A (1972) Structure of the excretion products of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine (BL 191) in man. Arzneimittelforschung/Drug Res 22: 1144–1151

    CAS  Google Scholar 

  • Hinze HJ, Grigoleit HG, Rethy B (1976) Bioavailability and pharmaeokinetics of pentoxifylline from Trental 400 in man. Pharmatherapeutica 1: 160–171

    CAS  Google Scholar 

  • Huppertz M (1976) Klinische Erfahrungen mit einem neuen Xanthinderivat (BL 191) bei der Behandlung akuter Hörminderungen oder Ertaubungen. Therapiewoche 23: 5008–5017

    Google Scholar 

  • Janaki S (1980) Pentoxifylline in strokes: a clinical study. J lnt Med Res 8: 56–62

    CAS  Google Scholar 

  • Keller H (1983) Treatment of chronic arterial circulatory disorders: double-blind trial with pentoxifylline (Trental 400). Pharmatherapeutica 3 [Suppl I]: 67–73

    Google Scholar 

  • Koppenhagen K, Wenig HG, Müller K (1977a) Measurement of cerebral blood flow following intravenous administration of pentoxifylline (Trental). Curr Med Res Opin 4: 521–528

    Article  PubMed  CAS  Google Scholar 

  • Koppenhagen K, Wenig HG, Müller K (1977b) The effects of pentoxifylline (Trental) on cerebral blood flow: a double-blind study. Curr Med Res Opin 4: 681–687

    Article  CAS  Google Scholar 

  • Lehrach F, Miller R (1981) Ergebnisse der klinischen Prüfung des Vasotherapeutikums 3,7-Dimethyl-1-(S-Oxohexyl)-xanthin. Arzneimittelforschung/Drug Res 21: 1171–1173

    Google Scholar 

  • Maak G (1986) Ambulante Hörsturztherapie mit Dextran und Pentoxifylline. Therapiewoche 36: 3347–3351

    Google Scholar 

  • Pettegrew J, Kopp S, Glonek T (1983) P-31 nuclear magnetic resonance study of pentoxifylline effect on experimental cerebral ischemia. Neurology 33 [Suppl 2]: 152

    Google Scholar 

  • Samlaska CP, Winfield EA (1994) Pentoxifylline. J Am Acad Dermatol 30:603–621

    Article  PubMed  CAS  Google Scholar 

  • Ward A, Clissold SP (1987) Pentoxifylline — a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50–97

    Article  PubMed  CAS  Google Scholar 

  • Wenig HG, Koppenhagen K (1981) Effects of pentoxifylline on cerebral and hepatic blood flow: scintigraphic measurements in patients with cerebrovascular insufficiency and liver diseases. In: Manrique U, Müller WE (eds) Disorders of blood flow: new therapeutic aspects. Excerpta Medica, Amsterdam, pp 95–106

    Google Scholar 

  • Wilt SG, Milward E, Zhou JM, Nagasato K, Patton H, Rüsten R, Griffin DE, O’Connor M, Dubois-Dalcq M (1995) In vitro evidence for a dual role of tumor necrosis factor-alpha in human immunodeficiency virus type 1 encephalopathy. Ann Neurol 37: 381–394

    Article  PubMed  CAS  Google Scholar 

  • Yaya R, Aznar J, Vaya A, Villa P, Santos T et al. (1985) Effect of di-pyridamole plus pentoxifylline in patients with diffuse cerebrovascular insufficiency. Thromb Haemost 54: 896

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. Hock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Müller-Spahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Neurochemie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Bezirkskrankenhaus Gabersee, Wasserburg/Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, Österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Wien

About this chapter

Cite this chapter

Hock, C., Müller-Spahn, F. (1999). Pentoxifyllin. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_57

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6400-6_57

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7315-2

  • Online ISBN: 978-3-7091-6400-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation